Medical/Pharmaceuticals APAC News & Press Release Distribution

Medical/Pharmaceuticals

All
Global

Update on overseas clinical trials progress of novel adjuvant COVID-19 vaccine ReCOV

TAIZHOU, China, Nov. 8, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that positive results were achieved for its primary vaccination Phase II study inthe Philippines and heterologous booster vaccinatio...

2022-11-08 15:17 2062

1 in 2 diabetics suffer from Peripheral Neuropathy[1] during their lifetime

* P&G Health, makers of Neurobion, embark on an effort to help people 'Put Life Back in Their Hands' for an improved quality of life. * Launched on World Diabetes Day across 18 countries, the campaign raises awareness on Peripheral Neuropathy in diabetes, and the importance of early identif...

2022-11-08 11:00 1033

1 in 2 diabetics suffer from Peripheral Neuropathy[1] during their lifetime

Cyagen and Neurophth Enter Global Strategic Collaboration to Develop AI-Designed AAV Gene Therapy Vectors for Ophthalmic Disorders

SANTA CLARA, Calif., Nov. 8, 2022 /PRNewswire/ -- Cyagen today announced a strategic collaboration with Neurophth Therapeutics, Inc. to co-develop next-generation AAV gene therapy vectors for specific types of genetic ophthalmic disorders. U...

2022-11-08 08:00 1884

Cyagen and Neurophth Enter Global Strategic Collaboration to Develop AI-Designed AAV Gene Therapy Vectors for Ophthalmic Disorders

Sirnaomics Doses the First Patient in Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Aesthetics Treatment

Data results expected to be available in 1H 2023 GAITHERSBURG, Md. and SUZHOU, China, Nov. 8, 2022 /PRNewswire/ -- Sirnaomics Ltd . (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeut...

2022-11-08 05:13 2146

Hummingbird Bioscience Announces Two HMBD-002 Poster Presentations at the Society for Immunotherapy of Cancer 2022 Annual Meeting

* VISTA blockade with HMBD-002 reprograms tumor associated macrophages and promotes cytotoxic T-cell response in preclinical studies * HMBD-002 in combination with anti-PD-1 treatment shows enhanced anti-tumor efficacy compared to monotherapy arms in preclinical studies * HMBD-002 is current...

2022-11-07 21:00 1641

Pulnovo Medical Inhales Tens of Millions Dollars Funding to Accelerate Global Growth

SHANGHAI, Nov. 7, 2022 /PRNewswire/ -- Pulnovo Medical Limited, a globally recognized OTM (From Operating Table to Market) innovative platform, today announced the successful close of its latest financing round. The financing was led by YuanBio Venture Capital, other investors includes Orbimed He...

2022-11-07 20:30 2341

HMA partners Baxter to deliver webinar series on patient care challenges and innovations

Series of educational webinars will bring together C-suite speakers from top hospitals inAsia, covering topics from burnout to healthcare-associated infections SINGAPORE, Nov. 7, 2022 /PRNewswire/ -- Asia's hospital administrations and healthcare executives are grappling with challenges evo...

2022-11-07 18:05 2272

Ascletis Announces Poster Presentation of Phase I, Single-Dose Study of ASC43F for NASH at AASLD Annual Meeting 2022

HANGZHOU and SHAOXING, China, Nov. 7, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces today that the abstract of a Phase I, Single-Dose Study of ASC43F for non-alcoholic steatohepatitis (NASH) has been reported at The Liver Meeting® 2022 of the American Association for...

2022-11-07 08:10 2001

Ascletis Announces Poster Presentation of Phase I, Single-Dose Study of ASC43F for NASH at AASLD Annual Meeting 2022

Innovent Releases Results of a Phase 3 Clinical Study of Tafolecimab（IBI306）in Chinese Patients with non- Familial Hypercholesterolemia at the American Heart Association (AHA) Scirntific Sessions 2022

ROCKVILLE, M.D. and SUZHOU, China, Nov 7, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and o...

2022-11-07 08:00 2706

Brexogen's Exosome Therapy for Atopic Dermatitis, 'BRE-AD01' Accepted for Phase 1 Clinical Trials by US FDA

First entry to clinical trial of exosome for atopic dermatitis The first exosome-based therapeutics in US clinical trial among Korean companies SEOUL, South Korea, Nov. 7, 2022 /PRNewswire/ -- The US FDA granted the initiation of the phase 1 clinical trial of 'BRE-AD01', an exosome- based ther...

2022-11-07 07:00 1863

Telix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study

Summary of Study Outcomes * ZIRCON Phase III study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) has met all of its primary and secondary endpoints * The study delivered co-primary endpoints of 86% sensitivity and 87% specificity and 93% posit...

2022-11-07 06:48 1654

Fosun Participates in the CIIE for the Fifth Consecutive Year with the Debut of Innovative Products in China

HONG KONG, Nov. 4, 2022 /PRNewswire/ -- The 5th China International Import Expo (hereinafter referred to as the "CIIE") will be held inShanghai from 5 November to 10 November. Fosun will participate in the CIIE for the fifth consecutive year with its overseas member companies and partners from th...

2022-11-04 14:43 3672

Roche introduces the navify brand for its digital health solutions at HLTH 2022

* Roche unifies its digital health portfolio under the navify brand, providing a range of next generation software solutions. * The navify portfolio uses digital solutions, analytics and data science to provide insights that address today's real-world challenges in health, enabling confident ...

2022-11-04 14:00 3650

NSW Health & Cicada Innovations celebrate Australia's biggest health startup training program with 1.1k participants in first year

SYDNEY, Nov. 4, 2022 /PRNewswire/ -- The NSW Health Commercialisation Training Program (CT Program), delivered by Aust...

2022-11-04 11:35 2463

NSW Health & Cicada Innovations celebrate Australia's biggest health startup training program with 1.1k participants in first year

LUMC to Fund New Clinical Trial of Cynata's Cymerus™ MSCs in Kidney Transplantation

Key Highlights: * Cynata to collaborate with Leiden University Medical Center (LUMC) in the Netherlands, in a new clinical trial in patients who have received a kidney transplant * Trial to be funded by LUMC; Cynata will supply iPSC-derived Cymerus mesenchymal stem cells (MSCs) at its cost t...

2022-11-04 09:15 2631

Werfen to Acquire Immucor, Inc., Expanding its Presence in Specialized Diagnostics

* Werfen enters into an agreement to acquire Immucor, Inc., a privately held, US-based corporation, with a solid global presence in transfusion and transplant in vitro diagnostics * The transaction is expected to close during the first half of 2023 BARCELONA, Spain, Nov. 4, 2022 /PRNewswire/ ...

2022-11-04 03:24 2860

Werfen to Acquire Immucor, Inc., Expanding its Presence in Specialized Diagnostics

Aquavit Celebrates Judgment Imposing Permanent Ban On Counterfeiters

NEW YORK, Nov. 4, 2022 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. ("Aquavit") secured a long-awaited and much-deserved judgment against counterfeiters. After nearly four years of court proceedings, the Honorable Valerie E. Caproni ofthe United States District Court for the Southern District o...

2022-11-04 01:37 2708

Kira Pharmaceuticals Presents Complete Data from Phase 1 SYNERGY-1 Trial of KP104 at American Society for Nephrology Kidney Week 2022

Biomarker data demonstrates proof-of-concept for KP104's dual-targeting mechanism via dose-dependent inhibition of alternative and terminal pathways and supports intravenous and subcutaneous administration of KP104 in phase 2 studies CAMBRIDGE, Mass. and SUZHOU, JIANGSU, China, Nov. 3, 2022 /PRN...

2022-11-03 21:30 2294

Merck KGaA, Darmstadt, Germany and p-Chip Corporation Collaborate to Improve Trust and Transparency in Machine-to-Machine Driven Industrial Value Chains

CHICAGO, Nov. 3, 2022 /PRNewswire/ -- Merck KGaA, Darmstadt, Germany, a leading science and technology company, and p-Chip Corporation, a company that is revolutionizing the tracking of physical products and materials with its breakthrough microtransponder technology, today announced the conclusi...

2022-11-03 19:00 2475

Malaysia Seeks Strategic Global Partnerships to Accelerate Its Growth Trajectory As A Preferred Healthcare Destination

Explore the potentials of Malaysia Healthcare at World Travel Market London 2022 LONDON, Nov. 3, 2022 /PRNewswire/ -- Malaysia Healthcare is strengthening its global proposition for preventive healthcare via strategic partnerships at the World Travel Market 2022 ("WTM") in London.

2022-11-03 18:16 1984

Malaysia Seeks Strategic Global Partnerships to Accelerate Its Growth Trajectory As A Preferred Healthcare Destination

1 ... 109 110 111112113 114 115 ... 383